Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
- Status
- RECRUITING
- Phase
- PHASE2
The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab
- Status
- RECRUITING
- Phase
- PHASE4
A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC
- Status
- WITHDRAWN
- Phase
- PHASE2
A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
- Status
- COMPLETED
- Phase
- PHASE3
Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC
- Status
- WITHDRAWN
- Phase
- PHASE1
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
- Status
- RECRUITING
- Phase
- PHASE3
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Combined Decompressive Spine Radiosurgery and Pembrolizumab
- Status
- TERMINATED
- Phase
- EARLY_PHASE1